All In Biotech

Drug Trial Radar · NCT06699212

A Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab in First-line Treatment of Locoregional Recurrent Squamous Cell Carcinoma of the Head and Neck With No Distant Metastases

A Phase 3 Multicenter, Randomized, Open-label Study of ASP-1929 Photoimmunotherapy in Combination With Pembrolizumab Versus Standard of Care in the First-line Treatment of Patients With Locoregional Recurrence of Squamous Cell Carcinoma of the Head and Neck (HNSCC) With No Distant Metastases

Last checked: Nov 20, 2026Latest source record: Oct 15, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 412 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

412

Planned (sponsor's estimate)

Start

Dec 24, 2024

Primary completion

Sep 2028

Study completion Sep 2028

Sponsor

Lead sponsor
Rakuten Medical, Inc.Industry
Sponsor type
Industry
First posted
Nov 21, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 3
Allocation
Randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this clinical trial is to learn if ASP-1929 photoimmunotherapy (PIT) in combination with pembrolizumab works to treat recurrent squamous cell cancer of the head and neck (HNSCC) with no distant metastases. It will also learn about the safety of ASP-1929 PIT in combination with pembrolizumab. Researchers will compare ASP-1929 PIT in combination with pembrolizumab to pembrolizumab alone or pembrolizumab plus chemotherapy (carboplatin or cisplatin, plus 5-fluorouracil or paclitaxel or docetaxel) according to physician's choice (control arm). The overall primary study hypothesis being tested is whether ASP-1929 PIT plus pembrolizumab combination treatment improves the overall survival (OS) of the population defined by the inclusion/exclusion criteria over the control arm.

Conditions

  • Recurrent Head and Neck Squamous Cell Carcinoma

Interventions

  • ASP-1929 PhotoimmunotherapyCombination product

    ASP-1929 IV infusion followed by illumination with light dose of 50 J/cm\^2 for superficial lesions and 100 J/cm for interstitial lesions within 24 +/- 4 hours after the end of ASP-1929 infusion (up to 24 months)

  • PembrolizumabBiological

    200 mg Q3W or 400 mg Q6W, IV infusion over 30 minutes (up to 24 months)

  • CarboplatinDrug

    Area under the curve (AUC) 5 mg/mL/min IV infusion, Q3W up to 6 cycles

  • CisplatinDrug

    100 mg/m\^2 IV infusion, Q3W up to 6 cycles

  • 5-fluorouracilDrug

    1000 mg/m\^2 per day from Days 1-4 of each cycle, IV infusion, Q3W up to 6 cycles

  • PaclitaxelDrug

    100 mg/m\^2 IV infusion given on Days 1 and 8, Q3W up to 6 cycles or 175 mg/m\^2 IV infusion given on Day 1, Q3W up to 6 cycles

  • DocetaxelDrug

    75 mg/m\^2 IV Infusion, Q3W up to 6 cycles

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall survival (OS)Time frame: Up to approximately 48 months

Locations

22 sites in 3 countries. Site status is shown where the registry gives one.

  • City of Hope

    Duarte, California · Recruiting

  • University of Miami

    Miami, Florida · Recruiting

  • Tampa General Hospital

    Tampa, Florida · Recruiting

  • University of Kentucky Medical Center

    Lexington, Kentucky · Withdrawn

  • Thomas Jefferson University, Sidney Kimmel Cancer Center

    Philadelphia, Pennsylvania · Recruiting

  • Rhode Island Hospital

    Providence, Rhode Island · Recruiting

  • Avera Cancer Institute

    Sioux Falls, South Dakota · Recruiting

  • University of Texas, MD Anderson Cancer Center

    Houston, Texas · Recruiting

  • Aichi Cancer Center

    Aichi, Japan · Recruiting

  • Hiroshima University Hospital

    Hiroshima, Japan · Recruiting

  • Kyoto Prefectural University of Medicine

    Kyoto, Japan · Recruiting

  • Tokyo Medical University Hospital

    Tokyo, Japan · Recruiting

  • Tottori University Hospital

    Yonago, Japan · Recruiting

  • Kaohsiung Medical University Chung-Ho Memorial Hospital

    Kaohsiung City, Taiwan · Recruiting

  • China Medical University

    Taichung, Taiwan · Recruiting

  • Taichung Veterans General Hospital

    Taichung, Taiwan · Recruiting

  • Chi Mei Hospital

    Tainan, Taiwan · Recruiting

  • National Taiwan University Hospital

    Taipei, Taiwan · Recruiting

  • MacKay Memorial Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Veterans General Hospital

    Taipei, Taiwan · Recruiting

  • Taipei Municipal Wanfang Hospital

    Taipei, Taiwan · Recruiting

  • Linkou Chang Gung Memorial Hospital

    Taoyuan City, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.